Fatty liver disease

Apr 04, 2019

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019

Mar 27, 2019

DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)

Mar 26, 2019

The Kinetix Group and Consulting at McCann Health's Research Report on Quality Measures for Nonalcoholic Steatohepatitis (NASH) to Be Presented at ISPOR 2019

Mar 12, 2019

Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population

Mar 08, 2019

TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights

Feb 20, 2019

Amsety and Fatty Liver Foundation are Partnering to Raise Funds for Liver Health Awareness Through the KISS AND CLICK Challenge

Feb 13, 2019

Second Edition of International NASH Day Announced Under a New Coalition Leadership

Jan 17, 2019

Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results

Dec 18, 2018

RSNA: MRI Effective for Monitoring Liver Fat in Obese Patients

Nov 27, 2018

Nonalcoholic Steatohepatitis (NASH) Market Analysis, Market size, Epidemiology, Leading companies and Competitive Analysis by DelveInsight